Table 4.
The studies evaluating the role of neutrophil to lymphocyte in urothelial cancer on chemotherapy.
| Study | Year | Cases | Site | Stage | Assessment and treatment | Threshold | Outcomes |
|---|---|---|---|---|---|---|---|
| Rossi et al. (74) | 2015 | 292 | Bladder + Ureter | Advanced or Metastatic | Pre/Follow up-Chemotherapy | 3/Kinetics | PFS, 2.76 (1.92–3.96), P < 0.001 OS, 3.15 (2.13–4.66), P < 0.001 |
| Taguchi et al. (75) | 2015 | 185 | Bladder + Ureter | Metastatic | Pre-Chemotherapy | 3 | CSS, 1.48 (1.01–2.17), P = 0.043 OS, 1.49 (1.02–2.18), P = 0.040 |
| Auvray et al. (76) | 2017 | 280 | Bladder + Ureter | Metastatic | Pre-Chemotherapy | 3.2 | OS, 1.36 (1.23–1.51), P < 0.001 PFS, 1.18 (1.05–1.33), P =0.005 |
| Su et al. (77) | 2017 | 256 | Bladder + Ureter | Metastatic | Pre-Chemotherapy | 3 | OS 1.60 (1.21–2.31), P = 0.001 |
| Tan et al. (55) | 2018 | 150 | Bladder | Advanced or Metastatic (cT4bN0M0 or TxN1-3M0 or TxNxM1) | Pre-Chemotherapy | 3 | OS 5.06 (2.88–8.88), P < 0.001 |
CSS, cancer specific survival; HR, hazard ratio; OS, overall survival; PFS, progression free survival; RC, radical cystectomy; RFS, recurrence free survival; RNU, radical nephroureterectomy.